↓ Skip to main content

American Association for Cancer Research

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations

Overview of attention for article published in Molecular Cancer Therapeutics, June 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

twitter
15 X users
patent
2 patents

Citations

dimensions_citation
54 Dimensions

Readers on

mendeley
29 Mendeley